Scleroderma Highlights
- Abstract #1373: High Nt-pro Brain Natriuretic Peptide and Low Carbon Monoxide Lung Diffusion Capacity are Independent Predictors of the Occurrence of Pre-capillary Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis
- Abstract # 2163: A Multi-Center Placebo-Controlled “In-Life” Study of MQX-503 in Patients with Raynaud Phenomenon
- Abstract #L12: A Multi-center Crossover Study of MQX-503, a Topical Formulation of Nitroglycerin, in Patients with Raynaud’s phenomenon
- Abstract #1370: Use of the Exercise Echocardiogram in the Diagnosis of Pulmonary Hypertension in Systemic Sclerosis
- Abstract #2166: Ambrisentan Therapy for Pulmonary Arterial Hypertension Associated with Connective Tissue Diseases
- Abstract #1371: Assessment of Heart Involvement in Systemic Sclerosis by Cardiac Magnetic Resonance Imaging in 50 Patients
- Abstract #2 : Skin Thickness Progression Rate in Systemic Sclerosis with Diffuse Cutaneous Involvement: A Predictor of Outcome
- Abstract # 32: Imatinib Mesylate Treatment Improves Skin Changes of Nephrogenic Systemic Fibrosis
- Abstract # 2148 Epigenetic Regulation in Scleroderma: High-Throughput Dna Methylation Profiling of Ssc Fibroblasts and Microvascular Endothelial Cells and the Central Role for Nos3 and Fli1 Epigenetic Repression in the Emergence of Ssc Cellular Phenotype
